Nyxoah S.A.
HealthcareNASDAQ:NYXH · NASDAQ Global Market
-$0.10 today
Vol 1.07M · Avg 0.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-183.4%
avg -112.1%
ROIC
-88.9%
avg -49.1%
ROA
-76.1%
avg -43.8%
Analysis
ROA is currently the strongest return metric at -76.1% versus its period average of -43.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bruno Onkelinx | Chief Technical Officer | $1.72M | — | 54 | — | — |
Olivier Taelman | Chief Executive Officer & Executive Director | $1.01M | — | 54 | — | — |
Loic Moreau | President of International | $540,635.00 | — | 46 | — | — |
Robert Taub | Co-Founder & Chairman | $136,762.00 | — | 79 | — | — |
Jeyakumar Subbaroyan | Chief Science Officer | — | — | — | — | — |
John Landry | Chief Financial Officer | — | — | 53 | — | — |
Geeta Kaveti | Chief Compliance Officer | — | — | — | — | — |
Maggie McGowan | Chief HR Officer | — | — | — | — | — |
Scott Holstine | Chief Commercial Officer | — | — | 55 | — | — |
An Moonen | General Counsel | — | — | — | — | — |
Pearson Dennis | Investor Relations Associate | — | — | — | — | — |
Maurits S. Boon | Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +90.3% (9yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +90.3% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Prenetics Global Limited
NASDAQ:PRE
$367.72M
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Utah Medical Products, Inc.
NASDAQ:UTMD
$216.00M
KORU Medical Systems, Inc.
NASDAQ:KRMD
$183.73M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Who manages NYXH?
Nyxoah S.A. (NYXH) lists 12 active executives. The top listed executive is Bruno Onkelinx, Chief Technical Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.